Here’s a breakdown of teh references provided, formatted for clarity:
1. FDA Approval of Enfortumab Vedotin adn Pembrolizumab:
* Source: U.S. Food and Drug Management (FDA)
* Title: FDA Approves Enfortumab Vedotin-ejfv and Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer
* Link: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer
* Date Accessed: Not explicitly stated, but likely current as of the document’s creation.
2. Clinical Trial Publication:
* Authors: POWLES T, valdera BP, Gupta S, et al.
* Title: Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer.
* Journal: New England Journal of Medicine
* Date: 2024
* Volume/Issue/Pages: 390(10):875-888
* DOI: 10.1056/NEJMoa2312117
3. Chemotherapy Drug Shortage Resolution:
* Author: Reed T.
* Source: Axios
* Title: Critical chemo drug no longer in shortage
* Date: July 1, 2024
* Link: https://www.axios.com/2024/07/01/critical-chemo-drug-no-longer-in-shortage-vitals
* Date Accessed: October 18, 2025
4.Press Release – Padcev and Keytruda Results:
* Source: PR Newswire (Astellas and Pfizer)
* Title: Padcev plus keytruda, given before and after surgery, cuts the risk of recurrence, progression or death by 60% and the risk of death by 50% for certain patients with bladder cancer.
* Date: October 18, 2025
* Date Accessed: October 18, 2025
Key Observations:
* the references relate to advancements in bladder cancer treatment, specifically the combination of Enfortumab Vedotin and pembrolizumab.
* There’s a mix of primary research (the NEJM publication), regulatory information (the FDA approval), news reporting (Axios), and industry press releases.
* The date of access for the press release is the same as the release date, suggesting it was accessed immediately upon publication.
* The Axios article addresses a broader issue of chemotherapy drug shortages, which is relevant to cancer care in general.